Agenus Inc. (NASDAQ:AGEN) Short Interest Update

Agenus Inc. (NASDAQ:AGEN) was the recipient of a significant drop in short interest in the month of October. As of October 31st, there was short interest totalling 2,800,000 shares, a drop of 10.5% from the October 15th total of 3,130,000 shares. Based on an average daily volume of 393,300 shares, the short-interest ratio is presently 7.1 days. Currently, 13.2% of the shares of the company are sold short.

Agenus Price Performance

Shares of NASDAQ:AGEN opened at $2.72 on Friday. The firm has a market capitalization of $63.81 million, a price-to-earnings ratio of -0.24 and a beta of 1.39. The business’s 50 day simple moving average is $4.70 and its 200-day simple moving average is $8.67. Agenus has a 12 month low of $2.58 and a 12 month high of $19.69.

Analysts Set New Price Targets

Several research firms have issued reports on AGEN. HC Wainwright dropped their target price on Agenus from $8.00 to $7.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 12th. StockNews.com cut Agenus from a “hold” rating to a “sell” rating in a research report on Monday, August 12th. Finally, B. Riley reduced their target price on Agenus from $42.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday, August 14th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, Agenus currently has a consensus rating of “Hold” and an average price target of $10.00.

Institutional Trading of Agenus

Several large investors have recently bought and sold shares of the company. Point72 DIFC Ltd purchased a new stake in shares of Agenus in the 2nd quarter worth about $51,000. EP Wealth Advisors LLC acquired a new position in Agenus during the third quarter worth about $55,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Agenus in the second quarter valued at about $106,000. BNP Paribas Financial Markets grew its position in shares of Agenus by 81.3% in the first quarter. BNP Paribas Financial Markets now owns 188,414 shares of the biotechnology company’s stock valued at $109,000 after purchasing an additional 84,477 shares during the last quarter. Finally, HighTower Advisors LLC increased its stake in shares of Agenus by 46.1% during the 3rd quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock worth $122,000 after purchasing an additional 7,530 shares in the last quarter. Institutional investors and hedge funds own 61.46% of the company’s stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.